Drug Trial Radar · NCT02718417
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
Last checked: Nov 20, 2026Latest source record: Jul 14, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
998
Actual
Start
May 19, 2016
Primary completion
Sep 7, 2018
Study completion May 16, 2019
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 24, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy. The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.
Conditions
- Ovarian Cancer
Interventions
carboplatinDrug
Given Q3W during chemotherapy phase
paclitaxelDrug
Investigator choice of weekly or Q3W during chemotherapy phase
AvelumabDrug
Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
AvelumabDrug
Given as single agent in maintenance portion Q2W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR)Time frame: Baseline to progression of disease or discontinuation from the study or death, whichever occurred first (maximum duration of 27 months)
Locations
319 sites in 25 countries. Site status is shown where the registry gives one.
Alabama Oncology
Alabaster, Alabama
Alabama Oncology
Bessemer, Alabama
Alabama Oncology, Bruno Cancer Center
Birmingham, Alabama
Alabama Oncology
Birmingham, Alabama
Alabama Oncology
Birmingham, Alabama
Alabama Oncology
Birmingham, Alabama
Alabama Oncology
Birmingham, Alabama
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona
Arizona Oncology Associates, PC - HAL
Phoenix, Arizona
Arizona Oncology Associates, PC - HAL
Scottsdale, Arizona
Arizona Oncology Associates, PC - HAL
Tempe, Arizona
Arizona Oncology Associates, PC-HOPE
Tucson, Arizona
Arizona Oncology Associates, PC-HOPE
Tucson, Arizona
Highlands Oncology Group
Fayetteville, Arkansas
Highlands Oncology Group
Rogers, Arkansas
Oso HomeCare
Irvine, California
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California
Medical Center, Cedars-Sinai
Los Angeles, California
Gynecologic Oncology Associates
Newport Beach, California
Chao Family Comprehensive Cancer Center
Orange, California
Hematology-Oncology Medical Group of Orange County
Orange, California
Medical Oncology Care Associates
Orange, California
St. Joseph Hospital of Orange
Orange, California
The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange
Orange, California
UC Irvine Health
Orange, California
University of California, Irvine/UC Irvine Health
Orange, California
California Pacific Medical Center - Medical Office Building
San Francisco, California
California Pacific Medical Center - Van Ness Campus
San Francisco, California
California Pacific Medical Center - Davies Campus
San Francisco, California
Bryan Hemming Cancer Care Center - California Pacific Medical Center
San Francisco, California
California Pacific Medical Center - Pacific Heights Outpatient Pharmacy
San Francisco, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
California Pacific Medical Center-Research Institute
San Francisco, California
Palo Alto Medical Foundation Group
San Francisco, California
Sansum Clinic
Santa Barbara, California
Sansum Clinic
Solvang, California
Rocky Mountain Cancer Centers
Aurora, Colorado
Rocky Mountain Cancer Centers
Boulder, Colorado
Rocky Mountain Cancer Centers
Lakewood, Colorado
C/O Thomas Ferencz, RPh, BCOP, Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
Showing 40 of 319 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.